<DOC>
	<DOCNO>NCT01087424</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety R-miniCHOP elderly patient diffuse large B-Cell lymphoma ( DLBC ) Lymphoma age 80 year measure overall survival .</brief_summary>
	<brief_title>Mini-CHOP Rituximab Patients Aged Over 80 Years</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large Bcell lymphoma ( WHO classification ) . DLBCL small cell infiltration bone marrow lymph node may include . Aged 80 year . Ann Arbor stage I bulky , II , III IV Ageadjusted International Prognostic Index equal 0 , 1 , 2 3 . Patient non previously treat . ECOG performance status ≤ 2 . With minimum life expectancy 3 month . Negative HIV , HBV HCV serologies test ≤ 4 week ( except vaccination ) . Having previously sign write informed consent Any histological type lymphoma . Any history treat nontreated indolent lymphoma . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any serious active disease ( accord investigator 's decision ) . Poor renal function ( creatinin level &gt; 150µmol/l ) , poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration . Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>80 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
</DOC>